-
Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has announced the publication of the Phase I clinical study results for its CTLA-4 antibody porustobart (HBM4003) in combination with Junshi Biosciences’ PD-1 inhibitor toripalimab. This combination is aimed at treating advanced…
-
Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a partnership with US biotechnology company OverT Bio, Inc. to develop next-generation cell therapies targeting solid tumors. The collaboration will leverage Nona’s heavy-chain antibody (HCAb) Harbour Mice platform, with no financial specifics disclosed. Nona Bio’s HCAb…
-
Nona Biosciences Partners with Alkyon Therapeutics to Develop Next-Generation Immunotherapies
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic partnership with U.S. biotechnology company Alkyon Therapeutics, Inc. (AlkyonTx). The collaboration aims to develop next-generation immunotherapy and other targeted therapy applications, leveraging Nona’s proprietary Harbour Mice fully human antibody platform. The financial details of the…
-
Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has reported a decline in its financial performance for the first half of 2024. The company’s overall revenues have dropped by 42.2% year-on-year to RMB 168 million (USD 23.7 million), with profits…
-
Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic collaboration with US-based Umoja Biopharma to co-develop multi-target antibody therapies. The partnership will leverage Nona’s proprietary fully human heavy chain only antibody (HCAb) technology to create innovative CAR-T cell therapy drug candidates generated in vivo.…
-
Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic cooperation agreement with Alaya.bio, a France-based polymer delivery platform company. This collaboration aims to harness their respective strengths to streamline the development, manufacturing, and administration of chimeric antigen receptor (CAR)-T therapies through precision targeting and…
-
Harbour BioMed Resubmits Biological License Application for Batoclimab in China
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has announced the resubmission of a biological license application (BLA) to China’s National Medical Products Administration (NMPA) for its drug candidate batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG). Batoclimab…
-
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
•
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement with the UK pharmaceutical giant AstraZeneca. The deal revolves around a pre-clinical monoclonal antibody (mAb) program, marking a substantial step forward in the development of innovative therapies. Under the terms of the agreement, AstraZeneca will…
-
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge in the US, has announced its financial results for the full year of 2023. The company reported a significant leap in revenues, reaching USD 89.5 million, which marks an increase of 119.9% year-on-year (YOY). In…
-
Harbour BioMed Partners with Boostimmune to Develop Novel ADC Therapies
•
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced an antibody drug conjugate (ADC) discovery cooperation agreement with South Korea-based ADC specialist Boostimmune, Inc. The financial details of the agreement have not been disclosed. As per the terms…
-
Harbour BioMed Gets FDA Green Light for Phase I Study of BsAb Targeting PD-L1 and CD40
•
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I study. The study will assess the safety, tolerability, pharmacokinetics, and anti-tumor…
-
Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer
•
Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview with FiercePharma.com on the margins of the JP Morgan Healthcare Conference that the company is contemplating additional strategic deals, particularly in the realm of antibody drug conjugates (ADCs), with a focus that may include Chinese…
-
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have jointly announced the licensing of their co-developed antibody-drug conjugate (ADC), HBM9033 (YL215), to Pfizer Inc.’s (NYSE: PFE) unit Seagen Inc. (NASDAQ: SGEN). According to the agreement, Seagen will secure global clinical development and commercialization rights…
-
Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a research partnership with Evive Biotech Ltd, a subsidiary of Chinese pharmaceutical company Yifan Pharmaceutical Co., Ltd (SHE: 002019). The collaboration will utilize Nona’s antibody technology platform, Harbour Mice, to focus on the discovery of dual…
-
Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration with U.S.-based biotech firm Lycia Therapeutics. This partnership grants Lycia access to Nona’s proprietary lysosomal targeting chimeras (LYTACs) platform, aimed at discovering and developing first-in-class therapeutics that target and degrade extracellular and membrane-bound proteins for…
-
Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has entered into a partnership with China-based GeneQuantum Healthcare. The collaboration aims to integrate the core technology platforms and professional expertise of both companies to empower the early discovery…
-
Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company with operations in the Netherlands, the United States, and China, has formed a strategic partnership with Ingenia Therapeutics, a pre-clinical biotech with a presence in the United States and South Korea. The collaboration aims to…
-
Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona’s proprietary technology to enhance BeiGene’s research capabilities. Financial details of the agreement have not…
